NEW YORK (GenomeWeb News) – Vermillion today said that it has inked an equity investment deal with certain investors to purchase up to $31.5 million of the firm's stock.

The Austin, Texas-based molecular diagnostics firm said that Oracle Investment Management, Jack Schuler, Matthew Strobeck, and other investors have agreed to make an initial investment in the company by purchasing 8 million shares of Vermillion common stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.